Drug Details

General Information of the Drug (ID: DR4674)
Name
Voriconazole
Synonyms
Voriconazole; 137234-62-9; Vfend; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; UK-109496; UK 109496; UK-109,496; UNII-JFU09I87TR; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol; C16H14F3N5O; (+/-)-Voriconazole; VCZ; CHEMBL638; JFU09I87TR; CPD000466350; (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; CHEBI:10023; (alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; 4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (alphaR,betaS)-; VRC; Voriconazol; DSSTox_CID_26485; DSSTox_RID_81656; DSSTox_GSID_46485; (2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-((1H)-1,2,4-triazol-1-yl)-butan-2-ol; (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; 4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (R-(R*,S*))-; Voriconazolum; Vorikonazole; Voriconazole [USAN:INN:BAN]; 188416-29-7; DRG-0301; SMR000466350; CAS-137234-62-9; Vfend (TN); VFEND I.V.; Pfizer; MFCD00905717; NCGC00164622-01; Voriconazole solution; Voriconazole, 98%; Voriconazole - Vfend; Voriconazole in combination with MGCD290; Voriconazole, (+/-)-; SCHEMBL36233; 2R,3S-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; MLS000759464; MLS001424082; MLS006010028; DTXSID5046485; Voriconazole (JP17/USP/INN); ZINC14864; AMY8903; SYN3012; Voriconazole, >=98% (HPLC); BCPP000019; DTXSID201019420; HMS2051N09; HMS3260M22; HMS3713F12; Pharmakon1600-01502346; Tox21_112241; Tox21_500150; Voriconazole 2.0 mg/ml in Methanol; AC-823; BDBM50333117; MFCD20488064; NSC759888; s1442; AKOS005145705; Tox21_112241_1; CCG-100941; CS-1227; DB00582; KS-1157; NC00191; NSC 759888; NSC-759888; SB17419; NCGC00164622-02; NCGC00164622-04; NCGC00164622-06; NCGC00260835-01; HY-76200; I992; Voriconazole related compound A RS [USP]; AB0013963; SW197571-2; C07622; D00578; J10329; W-5208; AB00639948-04; AB00639948-06; AB00639948_07; AB00639948_08; Voriconazole, VETRANAL(TM), analytical standard; 234V629; Q412236; J-006986; Z2616414875; UNII-USG4B1CD29 component BCEHBSKCWLPMDN-MGPLVRAMSA-N; Voriconazole, European Pharmacopoeia (EP) Reference Standard; Voriconazole, United States Pharmacopeia (USP) Reference Standard; (2R,3S)-2,3-bis(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; 2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl) butan-2-ol; Voriconazole, Pharmaceutical Secondary Standard: Certified Reference Material; (2R,3S)-2-(2,4-Difluoro-phenyl)-3-(5-fluoro-pyrimidin-4-yl)-1-[1,2,4]triazol-1-yl-butan-2-ol; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl) butan-2-ol; (2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol; (2r,3s)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol; 4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (alphaR,betaS)-rel-
    Click to Show/Hide
Molecular Type
Small molecule
Disease Aspergillosis [ICD-11: 1F20] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C16H14F3N5O
PubChem CID
71616
Canonical SMILES
CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O
InChI
1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1
InChIKey
BCEHBSKCWLPMDN-MGPLVRAMSA-N
CAS Number
CAS 188416-29-7
ChEBI ID
CHEBI:10023
TTD Drug ID
D0N3VR
DrugBank ID
DB00582
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Anidulafungin      Aspergillus nidulans     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Expression CYP51A1  Molecule Info 
Pathway MAP
                    In-vitro Model Aspergillus fumigatus Microorganism model Aspergillus fumigatus
                    Experimental
                    Result(s)		 The combination demonstrated synergy against the VCZ-R clinical isolate as well.
Target and Pathway
Target(s) Candida Cytochrome P450 51 (Candi ERG11)  Molecule Info  [3]
References
Reference 1 Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole. J Microbiol Immunol Infect. 2009 Apr;42(2):148-53.
Reference 2 In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus. Diagn Microbiol Infect Dis. 2012 Jun;73(2):135-7.
Reference 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
 Download Picture         KEGG Link